Lupin launches generic Kapvay tablets in US

08 Feb 2018 Evaluate

Lupin has launched Clonidine Hydrochloride extended-release tablets, 0.1 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Kapvay tablets had annual sales of around $66 million in the US (IQVIA MAT December 2017).

Lupin's Clonidine Hydrochloride ER tablets is the generic equivalent of Concordia International Corp's Kapvay tablets. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×